Sanofi reported slightly better than expected fourth-quarter results and reassuring guidance for 2017 on Feb. 8 - but analysts said real growth remains elusive for the French drugmaker and that its immediate prospects largely hinge on launching its Dupixent (duplimumab) therapy for atopic dermatitis and also winning a pending patent infringement case that threatens sales of its PCSK9 inhibitor Praluent (alirocumab).
The Paris-based group – which Olivier Brandicourt has revamped since taking over as CEO in April 2015 – also faces...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
